Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesClinical/Medical PolicyOscar Health bone turnover markers Coverage Update…
    Ask Trek AI about this page
    CurrentOscar HealthPolicy N/A

    Bone Turnover Markers Testing

    Customize your policy alerts

    Sign up for all Oscar Health policy alerts

    Know when Oscar Health releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines Oscar Health's coverage stance and clinical guidance for measurement of biochemical bone turnover markers (BTMs) in members with or at risk for osteoporosis and related conditions; intended for providers submitting claims and requesting authorizations.

    Policy Summary
    PayerOscar Health
    PolicyBone Turnover Markers Testing
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateOct 1, 2026
    Last ReviewJun 16, 2026
    Next Review DateJun 16, 2026
    Key ActionSubmit documentation demonstrating the specific BTM, clinical indication, and timing relative to therapy when requesting coverage or prior authorization.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    10/01/2026Policy effective date
    3Covered / not covered determinations
    ~20BTM analytes listed
    PINP, CTXReference BTMs emphasized

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    ≥20
    Evidence citations

    Coverage Determinations and Clinical Criteria

    Covered uses (meets criteria)

    Covered when ALL of the following are met for individuals with osteoporosis treated with bisphosphonates:

    Baseline and monitoring for bisphosphonate therapy

    • Baseline: a) To establish baseline levels before initiating bisphosphonate treatment
    • Initial monitoring: b) Every three months after initiation or change of therapy for the first year3 months
    • Long-term monitoring: c) Every two years when no medication changes have occurred2 years

    Not covered / does not meet criteria

    Specific non-covered indications: 2) Measurement of bone turnover markers to monitor teriparatide treatment

    DOES NOT MEET CRITERIA

    Diagnostic use: 3) As a diagnostic test for osteoporosis

    DOES NOT MEET CRITERIA

    Other high bone turnover conditions: 4) In the diagnosis and management of patients with other conditions associated with high rates of bone turnover

    DOES NOT MEET CRITERIA

    Guideline-based clinical use cases

    Guideline-supported scenarios where BTMs are useful (society statements):

    Monitoring therapy response/adherence: Use serum CTX to monitor antiresorptive therapy and P1NP to monitor anabolic therapy (measurements at baseline and at intervals such as 1-3, 3, 6, and 12 months are recommended by some groups). Significant reductions (eg, >LSC ~40% for CTX) indicate response to antiresorptives; increases indicate anabolic response.LSC approx 40% for CTX

    References: AACE/ACE, IOF/AFOS/ISCD, IOF/IFCC, ESCEO

    Assessing rapid bone loss or fracture risk: Elevated BTMs (eg, CTX, PINP) can predict more rapid rates of bone loss and have some prognostic value for fracture risk in situations where BMD is unavailable, but add only modest predictive value beyond clinical risk factors and BMD.AUC examples (eg, β-CTX AUC 0.63 in one cohort)

    References: AACE/ACE, IOF/ESCEO, Wei et al.

    CKD-specific guidance:

    Society Guidance Summary

    Guidance from multiple societies summarized:

    Society consensus on reference markers: ESCEO/IOF/IFCC reaffirm serum PINP and EDTA plasma β-CTX-I as reference BTMs; BALP and TRACP5b recommended for CKD-associated osteoporosis; PTH alone is insufficient in CKD.

    source: ESCEO/IOF/IFCC

    Clinical uses recognized by guidelines: BTMs may be useful for monitoring medication adherence and early efficacy (within months), assessing secondary causes of bone loss, and as research endpoints; some societies recommend confinement of measurement to specialist practice.within 6 months for treatment effect detection

    sources: RACGP, ROS, ISCD

    Limitations noted: Many guidelines state insufficient evidence for routine use in individual patients due to variability, lack of standardization, and limited predictive power for treatment response in some settings (eg, teriparatide). Very high marker levels should prompt evaluation for alternate causes.>1.5x upper reference limit triggers alternate-diagnosis workup

    Measurement of bone turnover markers (BTMs) to monitor therapy or for fracture-risk prediction in individuals with osteoporosis who are starting or receiving bisphosphonate treatment MEETS CRITERIA when all of the following are documented: baseline measurement prior to initiating bisphosphonate therapy; monitoring every 3 months after initiation or a therapy change during the first year; and routine monitoring every 2 years when no medication changes have occurred. Measurement of BTMs to monitor teriparatide treatment DOES NOT MEET CRITERIA. The policy further states that using BTMs as a diagnostic test for osteoporosis or for diagnosis/management of other high–bone-turnover conditions DOES NOT MEET CRITERIA because available published literature does not confirm the tests are required and beneficial for diagnosis and treatment.

    The North American Menopause Society (NAMS) and the ESCEO consensus both emphasize that routine use of bone turnover markers in the evaluation of all patients with osteoporosis is not recommended. NAMS notes BTMs cannot diagnose osteoporosis and have limited ability to predict fracture risk in clinical practice, and routine use to assess adherence or effectiveness is not recommended. ESCEO similarly cautions against routine monitoring to assess individual treatment effect, while acknowledging BTMs can help detect some causes of secondary osteoporosis and may be useful for assessing adherence when defined suppression exceeds the least significant change or reaches the lower half of young reference ranges.

    Guidance from Paget’s disease and ESCEO sources warns that BTMs should not be used as the sole diagnostic test for conditions such as Paget’s disease because elevations occur in many disease states (for example hyperparathyroidism, hyperthyroidism, malignancy, advanced renal failure, or recent fracture) and therefore cannot be interpreted in isolation; very high values (>1.5× upper reference limit) should prompt evaluation for alternate causes rather than being taken as a specific diagnosis.

    Per this policy, the use of bone turnover markers as a diagnostic test for osteoporosis is not medically necessary. The document specifies that BTM measurement for diagnosis of osteoporosis does not meet criteria owing to insufficient evidence that the tests are required or beneficial for diagnosing this condition.

    Several professional societies (including NAMS and ESCEO) do not support routine or universal BTM testing for diagnosis or for evaluation of all patients with osteoporosis; therefore, such routine testing would generally be considered not medically necessary under this policy. Societies note BTMs are primarily useful in research and select specialist settings rather than for broad, routine screening.

    Multiple organizations advise against routine use of BTMs for monitoring osteoporosis care in general practice. ESCEO and a systematic evidence review conclude there is insufficient evidence to recommend routine monitoring to predict response to therapies such as teriparatide. RACGP recognizes BTMs change early after treatment and can aid adherence monitoring in some studies but does not recommend routine use. As a result, routine or universal monitoring of BTMs in primary care is not supported by these guideline bodies.

    Applicable Codes, Test Methods, and Analytic Notes

    Applicable coding guidancemixed
    No codes listed
    Applicable CPT/HCPCS CodesCPT
    82523Collagen cross links, any method.
    83500Hydroxyproline; free.
    83505Hydroxyproline; total.
    83937Osteocalcin (bone gla protein).
    84080Phosphatase, alkaline; isoenzymes.
    NTX decrease confidence threshold
    Urinary NTX decrease thresholdTo be 90% confident a decrease is not due to variability: urinary NTX decrease ≥31%.
    Serum NTX decrease thresholdTo be 90% confident a decrease is not due to variability: serum NTX decrease ≥14%.
    Confidence level describedThresholds derived to provide ~90% confidence that observed decreases are not caused by biological or analytical variability.
    Inter-assay CV examples
    BAP longitudinal CV rangeReported longitudinal CVs for bone-specific alkaline phosphatase (BAP) range from 3.1% to 23.6%.
    NTX CV ranges

    Authorization, Documentation, and Billing Guidance for Providers

    Prior Authorization

    Authorization and benefit verification

    Services must meet authorization and medical necessity guidelines and coverage determinations are dependent on the member’s benefit coverage at the time of the request. Providers are responsible for submitting accurate documentation and appropriate coding; failure to follow coding/billing guidelines or current reimbursement policies may result in denial or recoupment.

    • Verify member benefits and that the requested BTM testing meets medical necessity per this policy before ordering or submitting a claim.
    • Confirm any Medicare/Medicaid specifications in the ‘Applicable State and Federal Regulations’ section when relevant.
    Prior Authorization

    Prior authorization may be appropriate for routine or non-guideline BTM use

    Some international groups endorse routine reimbursement and short-term monitoring with BTMs (eg, IOF/AFOS/ISCD recommendations), but multiple societies note limitations and recommend selective use — prior authorization may be reasonable when BTMs are requested for routine screening or outside guideline-indicated monitoring.

    Background and Evidence Summary

    Bone turnover markers (BTMs) are biochemical markers of bone formation (for example BSAP/BALP, osteocalcin, PINP) or bone resorption (for example NTX, CTX, TRACP5b) that may help assess fracture risk and rates of bone loss. Their clinical utility is limited by biological and assay variability and by lack of complete standardization; however, IOF/IFCC and related groups identify serum PINP and β-CTX (CTX) as reference markers commonly used for monitoring and research purposes. BTMs may add modest prognostic information beyond BMD and clinical risk factors, and are most often applied to monitor early treatment response or adherence rather than as sole diagnostic tools.

    BTM Definitions and Analytical Notes

    Bone turnover markers (BTMs)
    DefinitionBiochemical markers used to assess bone formation (e.g., BSAP/BALP, osteocalcin, PINP) or bone resorption (e.g., NTX, CTX, TRACP5b, DPD, PYD).
    Formation marker examplesBSAP/BALP; osteocalcin (OC); type I procollagen peptides (C1NP/P1NP).
    Resorption marker examplesUrinary hydroxyproline (HYP); pyridinoline (PYD); deoxypyridinoline (DPD); NTX; CTX; bone sialoprotein (BSP); TRACP5b; cathepsin K.
    Analytical variability / LSC
    Variability sourcesLaboratory (assay) and biological variability (coefficients of variation) substantially affect BTM results and interpretation.
    Least significant change (LSC)LSC thresholds are used to determine whether observed changes exceed expected variability and represent true change.
    Policy Summary
    PayerOscar Health
    PolicyBone Turnover Markers Testing
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateOct 1, 2026
    Last ReviewJun 16, 2026
    Next Review DateJun 16, 2026
    Key ActionSubmit documentation demonstrating the specific BTM, clinical indication, and timing relative to therapy when requesting coverage or prior authorization.
    SourceLink
    On This Page
    Coverage Determinations and Clinical CriteriaApplicable Codes, Test Methods, and Analytic NotesAuthorization, Documentation, and Billing Guidance for ProvidersBackground and Evidence SummaryBTM Definitions and Analytical Notes
    In CKD G3a-G5D, KDIGO suggests using PTH or bone-specific alkaline phosphatase to evaluate bone disease; KDIGO suggests not routinely measuring collagen-derived BTMs (eg P1NP, CTX) in these patients.
    CKD stages G3a-G5D

    References: KDIGO, IOF/IFCC, ESCEO

    Use in special programs and fracture liaison services: BTMs can be incorporated as short-term monitoring tools in FLS and osteoporosis care programs to improve adherence and treatment outcomes; some groups encourage reimbursement to support this use.measurement timing suggested (baseline, 3, 6, 12 months)

    References: IOF/AFOS/ISCD consensus, IOF/IFCC

    sources: ESCEO consensus, RACGP, ROS

    Reported CVs for NTX vary widely: longitudinal CVs 5.4% to 37.6%; within-run CVs for NTX reported 1.5% to 17.2%.
    Inter-laboratory variability noteProficiency testing showed markedly different results among labs even with identical assays, reflecting wide inter-laboratory CVs.
  1. If using BTMs for routine monitoring or outside guideline-supported indications, anticipate payer prior authorization requirements.
  2. Document the clinical rationale referencing guideline-supported scenarios if requesting authorization for non-standard use.
  3. Prior Authorization

    Prior authorization may be required for listed CPT/HCPCS codes

    Procedure codes for bone turnover marker tests are listed in the policy; check payer prior authorization rules for these specific CPT/HCPCS codes when prior authorization is required.

    • Relevant procedure codes include 82523, 83500, 83505, 83937, and 84080.
    • Confirm whether your payer requires prior authorization for the specific test code(s) being submitted.
    Step Therapy

    Step therapy

    Step therapy requirements are not specified in this policy.

    Note

    Use BTMs after initial risk/BMD assessment

    Guidelines recommend using BTMs primarily after initial clinical risk and BMD assessment — for monitoring treatment response, adherence, and to inform decisions (for example, bisphosphonate holidays), rather than as a first-line diagnostic test.

    • Obtain BMD and perform clinical risk assessment before using BTMs to guide management decisions.
    • Use BTMs to monitor response/adherence where guideline-supported (eg, serum CTX for antiresorptives, PINP/P1NP for anabolic agents).
    Note
    Documentation Required

    Documentation to support medical necessity

    Providers must submit accurate clinical documentation demonstrating that BTM testing is being performed for covered indications (for example, baseline measurement prior to initiating bisphosphonate therapy or monitoring at guideline-specified intervals).

    • Include clinical indication tying the test to covered uses (eg, baseline before bisphosphonate start; monitoring every 3 months during first year; biennial monitoring if stable).
    Documentation Required

    Suggested documentation elements

    Documentation should specify the exact bone turnover marker ordered (eg, serum CTX for antiresorptive monitoring, P1NP for anabolic therapy), the indication (baseline vs monitoring), and the timing relative to therapy (eg, baseline, 1–3 months, 3, 6, 12 months as recommended by some groups).

    • State whether the test is for baseline assessment, monitoring treatment response/adherence, or assessment during a bisphosphonate holiday.
    • Record timing of collection relative to treatment initiation or change (examples: baseline; 3 months; 6 months; 12 months).
    Billing Rule

    Test method and coding documentation

    Use FDA‑cleared assays when available or validated laboratory-developed tests (LDTs) per CLIA regulations; when submitting claims include the appropriate CPT/HCPCS procedure code(s) listed in the policy.

    • FDA-cleared BTM assays are listed in the policy (examples provided in the FDA section).
    • Report procedure codes such as 82523, 83500, 83505, 83937, or 84080 and attach supporting clinical documentation per payer rules.
    Denial Risk

    Denial risk for improper coding/documentation

    Claims may be denied or recouped if coding/billing guidelines or current reimbursement policies are not followed or if clinical documentation is inaccurate or insufficient to support medical necessity.

    • Ensure coding follows industry-standard guidelines and include supporting documentation linking the test to a covered indication.
    • Be aware that failure to follow payer-specific billing rules can result in claim denial or repayment requests.
    Denial Risk

    KDIGO measurement guidance

    KDIGO advises against routine measurement of collagen-derived BTMs (for example, P1NP, CTX) in patients with CKD stages G3a–G5D; ordering these tests outside KDIGO‑recommended indications may not be supported.

    • For CKD G3a–G5D, KDIGO suggests using serum PTH or bone-specific alkaline phosphatase instead of routine collagen-derived BTMs.
    • If treating patients with CKD, document rationale when ordering P1NP or CTX if deviating from KDIGO guidance.
    Denial Risk

    Conflict with government policy

    If this policy conflicts with an applicable government policy (such as a Medicare LCD/NCD or state Medicaid coverage rule), the government policy will govern determinations and may lead to denial of nonconcordant claims.

    • When applicable, check Medicare and state Medicaid coverage databases and follow those rules over this policy.
    • Document compliance with the controlling government policy when submitting claims or authorization requests.
    Inter-laboratory differencesProficiency testing and reproducibility studies demonstrate marked differences among laboratories even with identical assays.
    PINP
    Marker nameProcollagen type I N-terminal propeptide (PINP).
    RolePreferred bone formation marker for monitoring osteoporosis and treatment response per IOF/IFCC and ESCEO guidance.
    Use considerationsRecommended for monitoring anabolic therapy and as one of the reference BTMs for clinical application and research.
    CTX (β-CTX, s-CTX)
    Marker nameC-terminal cross-linking telopeptide of type I collagen (CTX; β-CTX, s-CTX).
    RolePreferred bone resorption marker for monitoring osteoporosis and antiresorptive therapy per IOF/IFCC and ESCEO guidance.
    Use considerationsUseful for monitoring response to antiresorptives (e.g., CTX reductions indicate suppression of resorption); part of reference marker pair with PINP.
    bALP / BALP
    Marker nameBone-specific alkaline phosphatase (bALP / BALP).
    RoleA bone formation marker less affected by renal failure; may be used when PINP or CTX are unavailable or in patients with CKD.
    CKD considerationRecommended by IOF/ESCEO/IFCC as a formation marker of potential use in CKD-associated osteoporosis assessment and monitoring.
    TRACP-5b
    Marker nameTartrate-resistant acid phosphatase 5b (TRACP-5b).
    RoleA bone resorption marker relatively less affected by renal failure; suggested for CKD-associated osteodystrophy and monitoring.
    CKD considerationIOF/ESCEO/IFCC recommend TRACP5b as a reference resorption marker in CKD-associated osteoporosis when PINP/CTX are limited by renal impairment.
    Reference BTMs
    Reference markers (general)ESCEO/IOF/IFCC recommend serum PINP and EDTA plasma β-CTX-I as the reference bone turnover markers for clinical use.
    CKD-specific referencesBALP (bALP) and TRACP5b are recommended as reference formation and resorption markers, respectively, in CKD-associated osteoporosis.
    Standardization needGuidance emphasizes the importance of assay standardization/harmonization to allow uniform decision limits and clinical application.
    Laboratory-developed test (LDT)
    DefinitionLaboratory-developed tests (LDTs) are tests developed and validated in-house by laboratories; they are regulated by CMS under CLIA '88 as high-complexity tests and are not approved or cleared by the FDA.
    Regulatory noteLDTs must be validated and performed in-house; FDA clearance/approval is not required for clinical use but LDTs are not FDA-approved/cleared.
    Clinical implicationProviders and payers should document test method (FDA-cleared assay vs LDT) when submitting claims or prior authorization requests.